Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 4/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776046 | 0.83 | MAPT (0.41) | HDAC2MMP2MMP3MAPT | |
| SCHEMBL18272869 | 0.83 | MAPT (0.41) | HDAC2MMP2MMP3MAPT | |
| SCHEMBL20997017 | 0.80 | MAPT (0.36) | HDAC2POLBMMP2MMP3MAPT | |
| SCHEMBL12040054 | 0.78 | CA1 (0.42) | ALDH1A1EPHX1HDAC2POLBMMP2 | |
| SCHEMBL20806763 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1EPHX1HDAC2POLB | |
| SCHEMBL12040121 | 0.78 | CA1 (0.42) | ALDH1A1EPHX1HDAC2POLBMMP2 | |
| SCHEMBL13186075 | 0.77 | POLB (0.33) | EPHX1HDAC2POLBMMP2MMP3 | |
| SCHEMBL24096090 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TDP1EPHX1HDAC2POLB | |
| SCHEMBL13434996 | 0.75 | CA1 (0.45) | TDP1HDAC2POLBMMP2MMP3 | |
| SCHEMBL13575213 | 0.75 | CA1 (0.45) | TDP1HDAC2POLBMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | ALDH1A1 1644/4885TDP1 3083/4885EPHX1 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.